Incomplete response in late-life depression: getting to remission

Area of Science:

• Geriatric Psychiatry
• Neuropharmacology
• Clinical Psychology

Background:

• Late-life depression frequently shows incomplete response to standard pharmacotherapy, posing significant public health challenges.
• Treatment-resistant late-life depression (TRLLD) is associated with increased morbidity, mortality, and caregiver burden.
• Limited empirical data exists for effective management strategies in TRLLD.

Purpose of the Study:

• To evaluate the efficacy of aripiprazole augmentation in older adults with treatment-resistant depression.
• To explore potential clinical and genetic moderators for personalized treatment approaches in TRLLD.
• To assess the sustainability of remission achieved with aripiprazole augmentation.

Main Methods:

• Pilot study involving 24 incomplete responders to sequential SSRI/SNRI pharmacotherapy.
• Aripiprazole augmentation was administered for 12 weeks.
• Remission and sustained remission were assessed over 6 months of continuation treatment.

Main Results:

• Aripipirazole augmentation resulted in remission in 50% of participants within 12 weeks.
• Sustained remission was observed in all participants who achieved remission during the 6-month continuation phase.
• Exploratory analysis planned for clinical and genetic moderators.

Conclusions:

• Aripiprazole augmentation appears to be a promising strategy for achieving remission in TRLLD.
• Sustained remission is achievable, suggesting long-term benefits.
• Further research is needed to identify personalized treatment strategies based on clinical and genetic factors.